ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1484

Value of Anti-RA33 Isotypes in an European Rheumatoid Arthritis Patient Cohort

Maresa Grundhuber1, Daniela Sieghart2, Günter Steiner2, Maryam Poorafshar3 and Sascha Swiniarski1, 1Thermo Fisher Scientific, Freiburg, Germany, Freiburg, Germany, 2Division of Rheumatology, Department of Internal Medicine III, Medical University Vienna, Austria, Vienna, Austria, 3Thermo Fisher Scientific, Uppsala, Sweden, Uppsala, Sweden

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Biomarkers, Diagnostic Tests, immunoglobulin (IG) and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Early diagnosis of rheumatoid arthritis (RA) leading to effective treatment is essential to improve prognosis and to prevent disease progression. Anti-cyclic citrullinated peptide (CCP) antibodies (ACPA) offers similar sensitivity, but higher specificity for RA than rheumatoid factor (RF) in early RA. In single analyte-testing scenarios, ACPA can detect approx. 70% of RA patients but fewer during early RA (~ 60%). As a biomarker for RA, anti-RA33 IgG antibodies are known to be specific, especially in the early stage of the disease. Recent studies show an emerging role of all three anti-RA33 isotypes in diagnosis and prognosis of RA1.

The aim of this study was to evaluate anti-RA33 isotypes IgM, IgA, and IgG for the diagnosis of early RA and to examine the added value compared to anti-CCP antibodies and RF within two independent European RA cohorts.

Methods:

The first cohort provided by Medical University of Vienna, Austria, includes in total 654 patient samples, 257 RA patient samples and 357 control samples; various autoimmune (n=128), non-autoimmune diseases (n=130) and healthy individuals (n=99). To validate the data, a second patient cohort (MATURA, United Kingdom) consisting of 295 patient samples, 100 RA patient samples, 75 autoimmune, 70 non-autoimmune diseases and 50 healthy subjects was measured. Serum samples of both cohorts were analyzed for the presence of anti-RA33, anti-CCP and RF (each IgM, IgA, IgG) using the EliATM instrument platform (Phadia AB, Uppsala, Sweden).

Results:

Analyzing both cohorts, one third of RA patients were positive for at least one of the anti-RA33 isotypes, whereas anti-RA33 IgM showed the highest sensitivity (23%) followed by IgA (12%) and IgG (9%). Both cohorts revealed a specific pattern of all three anti-RA33 isotypes with a diverse distribution among RA patients and little overlap between the immunoglobulin classes. The combination of all three anti-RA33 isotypes detects 26% of the seronegative RA patients and the specificity of each isotype is ≥90%.

Conclusion:

Anti-RA33 isotype distribution shows remarkably little overlap of IgM, IgA and IgG in European RA patient cohort. Therefore, the combination of all three anti-RA33 isotypes provides a considerable added value for the diagnosis of RA in the anti-CCP- and RF-negative group. To fully evaluate the importance of the different anti-RA33 immunoglobulin classes within the pathogenesis of RA, further investigations are required.

1 Sieghart, D; Platzer, A; Studenic, P; Alasti, F; Grundhuber, M; Swiniarski, S; Horn, T; Haslacher, H; Blüml, S Smolen, J; Steiner, G. Determination of Autoantibody Isotypes Increases the Sensitivity of Serodiagnostics in Rheumatoid Arthritis. Frontiers in Immunology; v:9 p:876; 2018


Disclosure: M. Grundhuber, Thermo Fisher Scientific, Phadia GmbH, 3; D. Sieghart, None; G. Steiner, Thermo Fisher Scientific, 2, 5; M. Poorafshar, Thermo Fisher Scientific, 3; S. Swiniarski, Thermo Fisher Scientific, Phadia GmbH, 3.

To cite this abstract in AMA style:

Grundhuber M, Sieghart D, Steiner G, Poorafshar M, Swiniarski S. Value of Anti-RA33 Isotypes in an European Rheumatoid Arthritis Patient Cohort [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/value-of-anti-ra33-isotypes-in-an-european-rheumatoid-arthritis-patient-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/value-of-anti-ra33-isotypes-in-an-european-rheumatoid-arthritis-patient-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology